and CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) equations accounted for an approximate 18% and 16% increase in eGFR. The consequences to this metric inflation were severe. Black ...

In a 2024 clinical practice guideline issued by the Kidney Disease: Improving Global Outcomes (KDIGO) organization ...

If cystatin C is not available, a creatinine-based estimated glomerular filtration rate (eGFR) should be used to assess patients at risk for CKD. But if it is available, GFR should be estimated ...

Cystatin C is emphasized as a preferred biomarker for accurate GFR measurement in CKD assessment. SGLT2i are recommended for CKD patients, regardless of diabetes status, for kidney and ...

ICU mortality was lower in the ARC group, 6.9% versus 14.5%, 𝑝 = 0.003. There was no concordance between the estimation of GFR by the CKD-EPI formula and GFR calculated from the 4-h urine. ARC is ...

Chronic kidney disease is defined as either kidney damage or GFR <60 mL/min/1.73m 2 for ≥3 months. Kidney damage is defined as pathologic abnormalities or markers of damage, including ...

In a 2024 clinical practice guideline issued by the Kidney Disease: Improving Global Outcomes (KDIGO) organization, a ...

Chronic Kidney Disease (CKD) signifies persistent kidney damage lasting over three months. The best indicator of kidney function is the Glomerular Filtration Rate (GFR), which measures how ...

Transdermal GFR System (TGFR) is a first-in-kind product for point of care assessment of kidney function in patients with normal or impaired renal function. The Clinical Kidney Journal in February ...

Chronic kidney disease is defined as either kidney damage or GFR <60 mL/min/1.73m 2 for ≥3 months. Kidney damage is defined as pathologic abnormalities or markers of damage, including ...

Chronic Kidney Disease (CKD) indicates prolonged kidney damage over three months, often undetectable until significant harm occurs. Key risk factors include diabetes, high blood pressure, and obesity.

Use of cystatin C and SGLT2 inhibitors were highlighted in the Kidney Disease: Improving Global Outcomes (KDIGO) organization's updated clinical practice guideline. In a synopsis of the recently ...